Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis
Go back to Vertex Selects Two Next-Generation Correctors, VX-659 and VX-445, to Advance into Phase 3 Development as Part of Two Different Triple Combination Regimens for People with Cystic Fibrosis| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 451.63 -7.36 (1.6%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $458.99 | 52 Week High | $134.71 | |||
| Open | $462.17 | 52 Week Low | $73.31 | |||
| Day High | $464.98 | P/E | N/A | |||
| Day Low | $450.39 | EPS | $-1.98 | |||
| Volume | 2,993,024 | |||||
